Mentioned in this article
Ventripoint Unveils New Integrated Product with ASCEND Cardiovascular
(TheNewswire)
|
|
|||||||||
Toronto, Ontario – TheNewswire –
August 18, 2023
– Ventripoint Diagnostics Ltd.
(”
Ventripoint
” or the ”
Company
“), (TSXV:VPT
)
(
OTC:VPTDF) is
thrilled to announce that Ventripoint and ASCEND Cardiovascular, LLC
have developed a new integrated product. Today’s announcement
marks a significant milestone in Ventripoint’s commitment to the
collaboration between the two companies. ASCEND fits perfectly into
Ventripoint’s roadmap for innovation and is a key step in the
company’s mission to improve patient’s lives and become the
standard of care.
ASCEND is seamlessly integrated with leading EHRs, and
imaging systems. Their existing technology has been installed at
1000+ top ranked healthcare facilities and 600+ health systems with
approximately 50,000 users across the United States.
Ventripoint has successfully and seamlessly integrated
its specialized AI-powered 3D Echo software application with
ASCEND’s diagnostic viewer, InView, and reporting application,
Cardiovascular Structured Reporting. This cardiovascular workflow
product provides an end-to-end solution that rivals other products on
the market. It is streamlined, smart, and effective for cardiology
reading, reporting, and diagnostics, thereby improving diagnosis and
monitoring of fetal, pediatric, and adult congenital heart disease.
“We are excited to embark on this collaborative
journey with ASCEND Cardiovascular,” stated Dr. Alvira Macanovic,
President & CEO of Ventripoint Diagnostics. “We see this
collaboration evolving progressively in its possibilities. We
believe that by integrating Ventripoint’s technology in diagnostic
medical imaging with ASCEND’s expertise in cardiology IT this will
be a successful integrated product. The product will offer a seamless
and comprehensive approach to diagnosing and treating cardiovascular
conditions.”
After months of development, Ventripoint stands ready
to successfully unveil this integrated product with its newest partner
at the 8
th
World Congress of Pediatric Cardiology and Cardiac Surgery
in Washington, DC later this month.
“This is an important milestone and validation of
ASCEND’s commitment to providers caring for children with heart
disease. We are excited to enable the routine, efficient use of
Ventripoint’s advanced 3D image analysis in pediatric
cardiology,” stated Dr. Jeff Soble, CEO of ASCEND.
As the collaboration between Ventripoint and ASCEND
continues to evolve, both companies remain committed to driving
innovation and excellence in cardiovascular health technology. This
integrated product marks an exciting milestone in the advancement of
cardiac care and solving today’s and anticipating tomorrow’s
challenges.
About Ventripoint Diagnostics
Ltd.
Ventripoint
has become known for
the application of AI (Artificial Intelligence) to echocardiography.
Ventripoint’s VMS products are powered by its proprietary AI
technology, which is the result of a decade of development and
provides accurate volumetric cardiac measurements equivalent to MRI.
Ventripoint’s VMS products are powered by its proprietary KBR
technology, which is the result of a decade of development and
provides accurate volumetric cardiac measurements equivalent to MRI.
This affordable, gold-standard alternative allows cardiologists
greater confidence in the management of their patients. Providing
better care to patients serves as a springboard and basic standard for
all of Ventripoint’s products that guide our future developments. In
addition, VMS+ is versatile and can be used with all ultrasound
systems from any vendor supported by regulatory market approvals in
the U.S., Europe and Canada. Learn more:
www.ventripoint.com
.
About ASCEND Cardiovascular
ASCEND Cardiovascular is a leader in innovating
cardiovascular solutions that empower the provider community to
improve cardiovascular care. Designed with openness in mind, their
solutions integrate with EHRs, medical devices, and other systems to
deliver seamless workflows that span procedure types and modalities. A
complete cardiovascular solution, ASCEND provides structured
reporting, image visualization, collaboration, and analytics that
improve efficiency, outcomes, and ROI. With decades of experience and
a practicing cardiologist at our helm, the ASCEND team brings
unparalleled “know how” in cardiology workflow, collaboration, and
IT offering limitless opportunities to improve clinical, operational,
and quality performance. Learn more:
www.ascendcv.com
.
For
further information, please
contact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy
of this news release.
Forward
Looking Statements
This news release contains forward-looking statements
and forward-looking information within the meaning of applicable
securities laws. The use of any of the words “expect”,
“anticipate”, “continue”, “estimate”,
“objective”, “ongoing”, “may”,
“will”, “project”, “should”,
“believe”, “plans”, “intends” and similar
expressions are intended to identify forward-looking information or
statements. The forward-looking statements and information are based
on certain key expectations and assumptions made by the Company.
Although the Company believes that the expectations and assumptions on
which such forward-looking statements and information are based are
reasonable,
undue reliance should not be placed
on the forward-looking statements and information because the Company
can give no assurance that they will prove to be correct.
Since forward-looking statements and information
address future events and conditions, by their very nature they
involve inherent risks and uncertainties. Actual results could differ
materially from those currently anticipated due to a number of factors
and risks. Factors which could materially affect such forward-looking
information are described in the risk factors in the Company’s most
recent annual management’s discussion and analysis that is available
on the Company’s profile on SEDAR at
www.sedar.com.
Readers are
cautioned that the foregoing list of factors is not exhaustive. The
forward-looking statements included in this news release are expressly
qualified by this cautionary statement. The forward-looking statements
and information contained in this news release are made as of the date
hereof and the Company undertakes no obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws.
Copyright (c) 2023 TheNewswire – All rights reserved.